

Table 7.6a
Immunosuppression Use for Induction, 1998 to 2007
Recipients with Pancreas After Kidney (PAK) Transplants

	Year of Transplant									
	1998	1999	2000	2001	2002	2003	2004	2005	2006	2007
Transplants	156	220	304	305	375	344	420	343	293	261
With Immunosuppression Info	152	217	298	303	372	336	408	336	283	247
Induction Drugs										
ALG	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Atgam/NRATG/NRATS	19.7%	8.3%	1.7%	0.3%	2.4%	0.6%	1.5%	3.3%	0.0%	1.2%
OKT3	15.8%	8.8%	3.0%	0.7%	1.3%	0.9%	0.2%	0.0%	0.7%	0.4%
Thymoglobulin	0.7%	30.0%	37.2%	50.5%	51.9%	50.9%	57.4%	53.9%	56.2%	61.9%
Zenapax	26.3%	36.9%	32.6%	33.3%	25.3%	9.5%	6.6%	6.8%	2.5%	2.0%
Simulect	9.9%	10.6%	17.1%	13.2%	8.3%	8.0%	5.4%	2.7%	6.7%	4.0%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	13.4%	19.1%	18.5%	13.4%	12.1%
No Induction Drugs Recorded	36.2%	33.6%	33.2%	25.1%	27.2%	25.9%	20.1%	21.7%	21.9%	19.8%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.